National Institutes of Health psilocybin research speaker series: State of the science, regulatory and policy landscape, research gaps, and opportunities

Dan Xi; Ann Berger; David Shurtleff; Farah Z Zia; Sean Belouin

doi:10.1016/j.neuropharm.2023.109467

National Institutes of Health psilocybin research speaker series: State of the science, regulatory and policy landscape, research gaps, and opportunities

Neuropharmacology. 2023 Jun 1:230:109467. doi: 10.1016/j.neuropharm.2023.109467. Epub 2023 Feb 27.

Authors

Dan Xi¹, Ann Berger², David Shurtleff³, Farah Z Zia⁴, Sean Belouin⁵

Affiliations

¹ National Institutes of Health (NIH), National Cancer Institute (NCI), Division of Cancer Treatment and Diagnosis (DCTD), Office of Cancer Complementary and Alternative Medicine (OCCAM), Rockville, MD, USA. Electronic address: xida@mail.nih.gov.
² NIH Clinical Research Center, Pain and Palliative Care, Bethesda, MD, USA. Electronic address: aberger@cc.nih.gov.
³ NIH, National Center for Complementary and Integrative Health (NCCIH), Bethesda, MD, USA. Electronic address: david.shurtleff@nih.gov.
⁴ National Institutes of Health (NIH), National Cancer Institute (NCI), Division of Cancer Treatment and Diagnosis (DCTD), Office of Cancer Complementary and Alternative Medicine (OCCAM), Rockville, MD, USA. Electronic address: ziaf@mail.nih.gov.
⁵ NIH Clinical Research Center, Pain and Palliative Care, Bethesda, MD, USA; United States Public Health Service (USPHS), Germantown, MD, USA; Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD, USA. Electronic address: sean.belouin@samhsa.hhs.gov.

PMID: 36858149
PMCID: PMC10163373 (available on 2024-06-01)
DOI: 10.1016/j.neuropharm.2023.109467

Abstract

The U.S. National Institutes of Health (NIH) convened a seminal first ever psychedelic drug substance-focused speaker series, from April 22 to June 10, 2021, titled the "NIH Psilocybin Research Speaker Series." This speaker series provided evidence-based scientific information to the public and the scientific community. Its aims were to assess the current state of the science, the regulatory and policy landscape, as well as to identify gaps in knowledge and understanding, ultimately serving to define future research needs. The highlights of the lectures and discussion from 26 national and international distinguished experts served as the basis for this Special Issue of Neuropharmacology. This article is part of the Special Issue on "National Institutes of Health Psilocybin Research Speaker Series".

Published by Elsevier Ltd.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Evidence Gaps*
National Institutes of Health (U.S.)
Policy
Psilocybin* / pharmacology
United States

Substances

Psilocybin

Grants and funding

Z99 CA999999/ImNIH/Intramural NIH HHS/United States